Featured Publications
Subcellular progression of mesenchymal transition identified by two discrete synchronous cell lines derived from the same glioblastoma
Kim S, Park S, Chowdhury T, Hong J, Ahn J, Jeong T, Yu H, Shin Y, Ku J, Park J, Hur J, Lee H, Kim K, Park C. Subcellular progression of mesenchymal transition identified by two discrete synchronous cell lines derived from the same glioblastoma. Cellular And Molecular Life Sciences 2022, 79: 181. PMID: 35278143, PMCID: PMC8918182, DOI: 10.1007/s00018-022-04188-3.Peer-Reviewed Original ResearchConceptsMesenchymal transitionCell linesAvailable single-cell RNA-seq dataMesenchymal transition (EMT) processCancer cell linesSame tissue samplesTherapeutic implicationsTumor samplesRecurrent samplesDriver mutationsGlioblastomaTissue samplesDistinct cancer cell linesGBM samplesIntratumoral heterogeneityTranscriptomic characteristics
2023
Patient-derived glioblastoma cell lines with conserved genome profiles of the original tissue
Kim S, Cho Y, Shin Y, Yu H, Chowdhury T, Kim S, Yi K, Choi C, Cha S, Park C, Ku J. Patient-derived glioblastoma cell lines with conserved genome profiles of the original tissue. Scientific Data 2023, 10: 448. PMID: 37438387, PMCID: PMC10338444, DOI: 10.1038/s41597-023-02365-y.Peer-Reviewed Original ResearchConceptsCell linesPatient-derived glioblastoma cell linesPatient-derived cell linesWhole exome sequencing datasetsExome sequencing datasetsGBM cell linesGlioblastoma cell linesSequence dataGenomic featuresLethal intracranial tumorSequencing technologiesSequencing datasetsMolecular markersWES datasetsGenome profilesMutational signaturesDruggable targetsNumber alterationsBiological credibilityGenomic profilesBiological platformMolecular characteristicsOriginal tissueTumor tissueGlioblastoma
2022
Different radiation responses induced by acquired gefitinib resistance in a non-small-cell lung cancer cell line
Kim J, Chowdhury T, Park H, Kim S, Lee C, Park C, Kim J, Kim I, Kim B, Kim T, Ku J, Lee J. Different radiation responses induced by acquired gefitinib resistance in a non-small-cell lung cancer cell line. Brain Tumor Research And Treatment 2022, 10: s366. DOI: 10.14791/btrt.2022.10.f-1244.Peer-Reviewed Original Research